Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...

SAN FRANCISCO -- Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy (MDT) in addition to systemic treatment, a meta-analysis of ...

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present two oral abstracts at the 2024 American ...

Stereotactic body radiotherapy (SBRT) is a safe treatment option for patients with oligometastatic cancer, with only 0.5% of patients experiencing severe acute toxicities within 6 months, according to ...

Addition of 6 months of androgen deprivation therapy to stereotactic body radiotherapy more than doubled PFS in hormone-sensitive oligorecurrent prostate cancer. Nearly all patients treated with the ...

For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently ...

Multimodal treatment including radical prostatectomy might lead to improved survival in patients with oligometastatic prostate cancer treated with ADT. Men with oligometastatic prostate cancer (OmPCa) ...

Metastasis-directed therapy added to ADT helps slow the progression of metastatic prostate cancer, a phase 2 trial finds. The addition of metastasis-directed therapy (MDT) to androgen deprivation ...

The MarketWatch News Department was not involved in the creation of this content. Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will ...